Lyrica vs. Gabapentin: Differences & Side Effects Explained

Lyrica and gabapentin are not the same drug, even though they work in a similar way and are often prescribed for the same conditions. Both belong to a drug class called gabapentinoids, and both can cause dependence, withdrawal, and serious side effects when combined with opioids or other sedatives. This article breaks down the key differences between Lyrica and gabapentin, compares their side effects, and explains what you need to know before stopping either one.

Lyrica vs. Gabapentin: What Sets Them Apart

Gabapentin and pregabalin, sold under the brand name Lyrica, are both gabapentinoids. They work by binding to the same target in the nervous system, the alpha-2-delta subunit of voltage-gated calcium channels, which reduces the release of excitatory neurotransmitters. That shared mechanism is why their effects, benefits, and risks overlap so much.

Still, they are distinct medications with different legal statuses, approved uses, and risk profiles.

Legal and scheduling status:

• One of the clearest practical differences between Lyrica and gabapentin is how they are regulated. Lyrica is a federally scheduled Schedule V controlled substance throughout the United States. Gabapentin is not federally controlled, though seven states currently classify it as Schedule V: Alabama, Kentucky, Montana, North Dakota, Tennessee, Virginia, and West Virginia. Many other states require gabapentin prescriptions to be reported to a prescription drug monitoring program without formally scheduling the drug.

• This legal gap exists despite the two drugs being pharmacologically related. Researchers and regulators have increasingly questioned whether gabapentin should receive the same federal Schedule V treatment as Lyrica, given that gabapentin misuse has grown substantially and the drug is frequently involved in overdose deaths alongside opioids.

How effective are they?

Both drugs help only a minority of chronic pain patients. NHS guidance suggests that only about one in seven people taking gabapentin or pregabalin for nerve pain experience meaningful improvement. Separate NHS sources put the figure at no more than 25% of patients with conditions like painful diabetic neuropathy or post-herpetic neuralgia seeing worthwhile benefit. That means the majority of people prescribed these drugs may be exposed to side effects and dependence risk without lasting pain relief.

Side Effects: Lyrica vs. Gabapentin

Shared Side Effects

Because Lyrica and gabapentin share the same mechanism, their side effect profiles are very similar. Common effects for both include:

• Dizziness and drowsiness
• Nausea and gastrointestinal discomfort
• Blurred vision
• Weight gain
• Memory and concentration problems
• Swelling in the hands and feet
• Fatigue

These effects are not rare. They are among the main reasons clinicians and patients consider reducing or stopping these medications.

Respiratory Depression: A Serious Risk for Both

One of the most serious shared risks is respiratory depression, particularly when either drug is combined with opioids, benzodiazepines, alcohol, or other central nervous system depressants. A review of FDA adverse event reports identified 49 cases of respiratory depression linked to gabapentinoids, including 12 deaths, with respiratory risk factors present in 92% of cases. Older adults, people with COPD or reduced lung function, and those already taking opioids face the highest respiratory risk from either drug.

Where Lyrica Differs

Lyrica carries some risks that are more prominently documented or more specific to pregabalin:

• Pregnancy risk. Pregabalin is associated with an increased risk of congenital malformations. Women of child-bearing age prescribed Lyrica should use effective contraception and discuss the risks with their prescriber before or during pregnancy. Gabapentin does not carry the same level of documented pregnancy concern, though it should still be reviewed carefully in this context.

• Renal accumulation. Both drugs are cleared primarily through the kidneys, but pregabalin accumulation in patients with renal impairment has been linked to serious adverse events. A published case report described a patient with diabetic nephropathy who experienced a tonic-clonic seizure four days after pregabalin was abruptly stopped, with no other likely cause identified. This case highlights why renal function must be monitored in anyone taking Lyrica, especially before stopping it.

• Misuse and dependence. Pregabalin has a well-documented misuse profile. Case series describe pregabalin use disorder requiring hospitalization and structured withdrawal management. A 2026 systematic review update found that gabapentinoid misuse increases overdose risk significantly when either drug is combined with opioids or benzodiazepines, with pregabalin carrying particularly strong evidence of misuse-related harm.

Withdrawal: What Happens When You Stop

Symptoms Are Similar for Both

Stopping either drug abruptly or reducing the dose too quickly can trigger withdrawal. The UK Medicines and Healthcare products Regulatory Agency strengthened its warnings in 2026, stating that withdrawal syndrome may occur when gabapentinoids are stopped suddenly and that tapering can take weeks or months for some patients.

Withdrawal symptoms for both drugs can include:

• Anxiety and agitation
• Insomnia
• Nausea and sweating
• Tremor and dizziness
• Rebound pain
• Confusion or depressed mood
• In severe cases: hallucinations, suicidal ideation, and seizures

When Symptoms Start

Symptoms typically begin within one to four days of abrupt cessation, though onset can occur as early as 12 to 48 hours. Pregabalin case literature documents withdrawal symptoms beginning 48 hours after stopping a 150 mg daily dose, and a seizure occurring four days after abrupt cessation in another patient. NHS patient guidance states that common withdrawal effects can occur within a day and last up to seven days.

Why You Should Not Stop Abruptly

A 2023 scoping review found only four eligible studies on gabapentinoid deprescribing interventions, which reflects how limited the formal evidence base is. Despite that gap, regulatory bodies, NHS guidance, and clinical case evidence all point to the same conclusion: both Lyrica and gabapentin should be tapered gradually under medical supervision, not stopped suddenly.

Typical supervised taper guidance suggests:

• Gabapentin: reduce by 100 to 300 mg every one to two weeks, with smaller steps at lower doses
• Pregabalin/Lyrica: reduce by 50 to 75 mg every one to two weeks, with slower reductions in older patients, those with renal impairment, or anyone with a history of psychiatric vulnerability or prior failed taper

If withdrawal symptoms appear during a taper, the right response is to pause the reduction and wait for symptoms to settle before continuing, not to return immediately to the original dose.

Who Faces the Highest Risk

Both drugs carry greater risk in certain groups. People who need the closest monitoring include those who:

• Take opioids, benzodiazepines, alcohol, or other sedatives alongside either drug
• Have reduced kidney function
• Are aged 65 or older
• Have a history of seizures or epilepsy
• Are pregnant or planning to become pregnant, especially with Lyrica
• Have a history of substance use disorder
• Are on high doses or have used either drug for a long time

Co-prescribing gabapentinoids with opioids is a particular concern. NHS guidance from multiple regions advises against routine long-term co-prescribing of opioids and gabapentinoids for chronic non-cancer pain because of increased mortality risk. The 2026 systematic review update found that among people with opioid use disorder, gabapentinoid use increased all-cause mortality, with even higher risk when combined with opioids and benzodiazepines together.

The Difference That Matters Most

The difference between Lyrica and gabapentin is not that one is safe and the other is dangerous. Both carry real risks of dependence, withdrawal, respiratory depression, and harm in combination with other sedatives. The clearest practical difference is legal: Lyrica is federally controlled everywhere in the United States, while gabapentin’s status depends on which state you are in.

From a clinical standpoint, the more important question is whether either drug is still helping you. NHS guidance recommends reviewing gabapentinoid prescriptions every six to twelve months for chronic pain patients to check whether the drug is still providing meaningful benefit. If it is not, a gradual, supervised taper is the right path, not indefinite continuation and not abrupt stopping.

If you or someone you care about is managing dependence on gabapentin, Lyrica, or other prescription medications, speaking with a specialist is the safest first step. Thoroughbred Wellness and Recovery offers medical detox support for prescription medication dependence, with personalized care available around the clock.